Cited 14 times in
Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김범경 | - |
dc.contributor.author | 김승업 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 성진실 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 원종윤 | - |
dc.contributor.author | 이혜원 | - |
dc.contributor.author | 정규식 | - |
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2018-07-20T08:07:48Z | - |
dc.date.available | 2018-07-20T08:07:48Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 0360-3016 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/160860 | - |
dc.description.abstract | PURPOSE: It is unclear whether the efficacy and safety of concurrent chemoradiation therapy (CCRT) and transarterial radioembolization (TARE) with 90Y are comparable in patients with locally advanced hepatocellular carcinoma. METHODS AND MATERIALS: In total, 209 treatment-naive patients with stage B or C cancer according to the Barcelona Clinic Liver Cancer classification who were treated with TARE or CCRT were analyzed. Propensity scores were calculated and matched at a 1:1 ratio for TARE versus CCRT using age, tumor size, tumor number, portal vein thrombosis, and Barcelona Clinic Liver Cancer staging. In the CCRT group, concurrent hepatic arterial infusion chemotherapy with 5-fluorouracil was delivered at a dosage of 500 mg/d during the first and last 5 days of radiation therapy (median, 45 Gy). Overall survival, freedom from progression, tumor response, and complication rate were compared between the TARE and CCRT groups. RESULTS: Among 209 patients, 124 (62 undergoing TARE and 62 undergoing CCRT) were selected after propensity score matching. Overall survival (TARE vs CCRT, 14.0 months vs 13.2 months, P=.435) and freedom from progression (6.9 months vs 7.8 months, P=.437) were comparable between the 2 groups. Objective response rates at 1 month after treatment were higher for CCRT than for TARE (46.8% vs 16.1%, P<.001), while objective response rates at 3 months were significantly higher for TARE than for CCRT (39.3% vs 21.4%, P=.04). There was no significant difference in long-term response rates (at 6 months and 1 year) between the 2 groups. The CCRT group experienced a higher rate of curative resection or liver transplantation after treatment than the TARE group, although the statistical significance was marginal (24.2% vs 11.3%, P=.060). Treatment-related complications were less frequent after TARE than after CCRT. CONCLUSIONS: Both treatments yielded comparable survival rates and long-term response rates in patients with intermediate- or advanced-stage hepatocellular carcinoma. The role of these modalities as a bridge to curative therapy requires further investigation. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Elsevier Science Inc. | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Age Factors | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antimetabolites, Antineoplastic/administration & dosage | - |
dc.subject.MESH | Carcinoma, Hepatocellular/mortality | - |
dc.subject.MESH | Carcinoma, Hepatocellular/pathology | - |
dc.subject.MESH | Carcinoma, Hepatocellular/therapy* | - |
dc.subject.MESH | Chemoembolization, Therapeutic/adverse effects | - |
dc.subject.MESH | Chemoembolization, Therapeutic/methods* | - |
dc.subject.MESH | Chemoembolization, Therapeutic/mortality | - |
dc.subject.MESH | Chemoradiotherapy/adverse effects | - |
dc.subject.MESH | Chemoradiotherapy/methods* | - |
dc.subject.MESH | Chemoradiotherapy/mortality | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil/administration & dosage | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Liver Neoplasms/mortality | - |
dc.subject.MESH | Liver Neoplasms/pathology | - |
dc.subject.MESH | Liver Neoplasms/therapy* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Portal Vein | - |
dc.subject.MESH | Propensity Score | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Tumor Burden | - |
dc.subject.MESH | Venous Thrombosis | - |
dc.subject.MESH | Yttrium Radioisotopes/therapeutic use | - |
dc.title | Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Jeong Eun Song | - |
dc.contributor.googleauthor | Kyu Sik Jung | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Kijun Song | - |
dc.contributor.googleauthor | Jong Yun Won | - |
dc.contributor.googleauthor | Hye Won Lee | - |
dc.contributor.googleauthor | Beom Kyung Kim | - |
dc.contributor.googleauthor | Seung Up Kim | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Jinsil Seong | - |
dc.contributor.googleauthor | Kwang-Hyub Han | - |
dc.identifier.doi | 10.1016/j.ijrobp.2017.05.049 | - |
dc.contributor.localId | A00385 | - |
dc.contributor.localId | A00487 | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A01956 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A02443 | - |
dc.contributor.localId | A03318 | - |
dc.contributor.localId | A03578 | - |
dc.contributor.localId | A04268 | - |
dc.relation.journalcode | J01157 | - |
dc.identifier.eissn | 1879-355X | - |
dc.identifier.pmid | 28871990 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0360301617309872 | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.alternativeName | Kim, Beom Kyung | - |
dc.contributor.alternativeName | Kim, Seung Up | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.alternativeName | Seong, Jin Sil | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.alternativeName | Won, Jong Yun | - |
dc.contributor.alternativeName | Lee, Hye Won | - |
dc.contributor.alternativeName | Jung, Kyu Sik | - |
dc.contributor.alternativeName | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | Kim, Beom Kyung | - |
dc.contributor.affiliatedAuthor | Kim, Seung Up | - |
dc.contributor.affiliatedAuthor | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | Seong, Jin Sil | - |
dc.contributor.affiliatedAuthor | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Won, Jong Yun | - |
dc.contributor.affiliatedAuthor | Lee, Hye Won | - |
dc.contributor.affiliatedAuthor | Jung, Kyu Sik | - |
dc.contributor.affiliatedAuthor | Han, Kwang Hyup | - |
dc.citation.volume | 99 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 396 | - |
dc.citation.endPage | 406 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol.99(2) : 396-406, 2017 | - |
dc.identifier.rimsid | 60744 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.